Document Detail

Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
MedLine Citation:
PMID:  23037807     Owner:  NLM     Status:  Publisher    
Colorectal carcinoma is one of the most frequent cancer diseases. For patients with this type of cancer, liver metastases are the main cause of death. Therefore, new therapeutic approaches are urgently needed to improve the outcomes. We found that both mRNA and protein levels of tissue inhibitor of metalloproteinase-3 (TIMP3) were decreased significantly in colorectal cancer tissue when compared with normal mucosa, suggesting that decrease of TIMP3 expression was correlated with malignant behavior of colorectal cancer. We evaluated the power of TIMP3, a new potent multiple functional molecule, as a biotheropeutic tool to treat cancer. Adenovirus-mediated TIMP3 transduction in CT26 colon cancer model demonstrated multiple effects to arrest cancer cell growth and induced massive apoptosis. Also, adenovirally transferred TIMP3 reduced adhesion, migration and invasion behaviors of CT26 cells in vitro. In vivo data showed that TIMP3 suppressed in vivo tumor growth and that liver metastasis was significantly reduced by TIMP3 transduction. This is the first systematic preclinical study to show that TIMP3 may be a potential molecular tool for colon cancer biological therapy.Cancer Gene Therapy advance online publication, 5 October 2012; doi:10.1038/cgt.2012.70.
H Lin; Y Zhang; H Wang; D Xu; X Meng; Y Shao; C Lin; Y Ye; H Qian; S Wang
Related Documents :
23374847 - Tumor-specific rna interference targeting pokemon suppresses tumor growth and induces a...
14651997 - Silibinin down-regulates survivin protein and mrna expression and causes caspases activ...
23213057 - Slc1a5 mediates glutamine transport required for lung cancer cell growth and survival.
23465717 - Ent-pimarane and ent-trachylobane diterpenoids from mitrephora alba and their cytotoxic...
23849787 - Lung cancer epidemiology in north sardinia, italy.
23370117 - Therapeutic applications of parp inhibitors: anticancer therapy and beyond.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-05
Journal Detail:
Title:  Cancer gene therapy     Volume:  -     ISSN:  1476-5500     ISO Abbreviation:  Cancer Gene Ther.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9432230     Medline TA:  Cancer Gene Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1] Department of Gastroenterology Surgery, Peking University People's Hospital, Beijing, China [2] Department of General Surgery, First Hospital of Tsinghua University, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
Next Document:  A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radio...